Top 5 Takeaways Significant Increase in cVDPV2 Cases: During January 2020–June 2021, there were 44 cVDPV outbreaks resulting in 1,335 paralytic cases, with 86% being cVDPV2. Introduction of Novel OPV2:
Author: Cody Micah Carmichael MPH, CPH
Gut Health and Endometriosis: New Study Uncovers Biomarkers for Non-Invasive Diagnosis Key Takeaways A new study reveals distinct stool metabolites in women with endometriosis, offering a pathway for non-invasive diagnosis.
Top 5 Takeaways Emergence of COVID-19-Associated Mucormycosis: Multiple cases of mucormycosis were reported in Arkansas following COVID-19 diagnosis, highlighting a new public health concern. Patient Demographics: The median age of
COVID-19: A Coronary Artery Disease Risk Equivalent with Genetic Implications Key Takeaways COVID-19, especially in hospitalized cases, is linked to an increased risk of major cardiovascular events (MACE). Hospitalization for
Top 5 Takeaways Unexpected Increase in Cases: An unexpected number of mucormycosis cases were reported among COVID-19 patients in Honduras between May and September 2021. Investigation Collaboration: The investigation was
PyFriday Tutorial: Analyzing Incidence Rates and Yearly Changes in Python Welcome to another PyFriday tutorial! Today, we are focusing on calculating and analyzing incidence rates of depression across multiple
Top 5 Takeaways Sharp Increase in Deaths: IMF-involved overdose deaths surged in midwestern (33.1%), southern (64.7%), and western (93.9%) regions during 2019-2020. Polysubstance Use: Approximately 40% of IMF-involved deaths also
CPH Focus: Evidence-Based Approaches to Public Health: Epidemiology – Measures of Disease Frequency: Incidence and Prevalence In this CPH Focus, we’ll dive deep into one of the fundamental topics in
Epi Explained: Understanding Morbidity and Mortality Morbidity and mortality are two critical concepts in public health and epidemiology. These terms help researchers and healthcare professionals assess the impact of diseases
Top 5 Takeaways High Booster Uptake: 18.7 million adults aged ≥65 years received a booster or additional primary dose, representing 44.1% of eligible individuals in this age group. Coverage Variation: